{
    "clinical_study": {
        "@rank": "152927", 
        "arm_group": [
            {
                "arm_group_label": "FG-4592 (TIW & BIW)", 
                "arm_group_type": "Experimental", 
                "description": "Study drug will be dosed TIW during the correction period, then twice weekly (BIW) during the maintenance period. Dose adjustments are allowed during the study."
            }, 
            {
                "arm_group_label": "Placebo (TIW & TIW)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Study drug will be dosed TIW during the correction period and TIW during the maintenance period. Dose adjustments are allowed during the study."
            }, 
            {
                "arm_group_label": "FG-4592 (TIW & TIW)", 
                "arm_group_type": "Experimental", 
                "description": "Study drug will be dosed three times weekly (TIW) during the correction period and TIW during the maintenance period. Dose adjustments are allowed during the study."
            }, 
            {
                "arm_group_label": "FG-4592 (TIW & QW)", 
                "arm_group_type": "Experimental", 
                "description": "Study drug will be dosed TIW during the correction period, then weekly (QW) during the maintenance period. Dose adjustments are allowed during the study."
            }, 
            {
                "arm_group_label": "Placebo (TIW & BIW)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Study drug will be dosed TIW during the correction period and BIW during the maintenance period. Dose adjustments are allowed during the study."
            }, 
            {
                "arm_group_label": "Placebo (TIW & QW)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Study drug will be dosed TIW during the correction period and QW during the maintenance period. Dose adjustments are allowed during the study."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of FG-4592 in the treatment\n      of anemia of Chronic Kidney Disease (CKD)."
        }, 
        "brief_title": "A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "There is a screening period of up to 6 weeks, a treatment period of 52 weeks, and a\n      post-treatment follow up period of 4 weeks. A total of 450-600 patients will be randomized\n      in a 2:1 ratio to receive either FG-4592 or Placebo in blinded fashion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic kidney disease,  Stage 3, 4, or 5, not receiving dialysis\n\n          -  Anemia qualified by measurements of hemoglobin values during screening\n\n          -  Additional blood work must be in a safe range for study entry\n\n          -  Body weight 45 to 160 kg\n\n          -  Willingness to use contraception if of child-bearing potential\n\n        Exclusion Criteria:\n\n          -  Treatment with an erythropoiesis-stimulating agent within 12 weeks prior to study\n             participation\n\n          -  More than one dose of intravenous iron within 12 weeks prior to study participation\n\n          -  Blood transfusion within 8 weeks prior to study participation\n\n          -  Active infection\n\n          -  Chronic liver disease\n\n          -  Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot\n\n          -  Uncontrolled blood pressure within 2 weeks prior to study participation\n\n          -  Renal cell carcinoma\n\n          -  History of malignancy, including multiple myeloma or other myelodysplastic syndrome\n\n          -  Chronic inflammatory disease that could impact red blood cell production\n\n          -  Any prior organ transplant, or a scheduled organ transplantation\n\n          -  Anticipated elective surgery that is expected to lead to significant blood loss, or\n             anticipated elective heart procedure\n\n          -  Gastrointestinal bleeding\n\n          -  Any prior treatment with FG-4592 or a HIF-PHI\n\n          -  Recent use of an investigational drug or treatment, or participation in an\n             investigational study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750190", 
            "org_study_id": "FGCL-4592-060"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FG-4592 (TIW & BIW)", 
                    "FG-4592 (TIW & TIW)", 
                    "FG-4592 (TIW & QW)"
                ], 
                "description": "Oral", 
                "intervention_name": "FG-4592", 
                "intervention_type": "Drug", 
                "other_name": "Roxadustat; ASP1517"
            }, 
            {
                "arm_group_label": [
                    "Placebo (TIW & TIW)", 
                    "Placebo (TIW & BIW)", 
                    "Placebo (TIW & QW)"
                ], 
                "description": "Oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "anemia", 
            "chronic kidney disease (CKD)", 
            "non-dialysis", 
            "Hemoglobin (Hb)", 
            "End-Stage Renal Disease", 
            "Erythropoeitin", 
            "ASP1517", 
            "Erythropoeisis stimulating-agent"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91910"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Northridge", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91325"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riverside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92505"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yuba City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95991"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cordoba", 
                        "country": "Argentina"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paolo", 
                        "country": "Brazil"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Selayang", 
                        "country": "Malaysia"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Luis Potosi", 
                        "country": "Mexico"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pasig", 
                        "country": "Philippines"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Australia", 
                "Brazil", 
                "Hong Kong", 
                "Korea, Republic of", 
                "Malaysia", 
                "Mexico", 
                "New Zealand", 
                "Peru", 
                "Philippines", 
                "Singapore", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis", 
        "overall_contact": {
            "email": "060study@fibrogen.com", 
            "last_name": "Clinical Trial Coordinator", 
            "phone": "1-415-978-1672"
        }, 
        "overall_official": {
            "affiliation": "FibroGen", 
            "last_name": "Charles Bradley, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Malaysia: Ministry of Health", 
                "Taiwan : Food and Drug Administration", 
                "Korea: Ministry of Food and Drug Safety", 
                "Hong Kong: Department of Health", 
                "Thailand: Food and Drug Administration", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Chile: Ministry of Health", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Peru: General Directorate of Pharmaceuticals, Devices, and Drugs", 
                "Brazil: National Health Surveillance Agency", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Singapore: Health Sciences Authority", 
                "Philippines : Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy of FG-4592 in achieving hemoglobin response (as defined in protocol) in CKD subjects not receiving dialysis", 
            "measure": "Efficacy of FG-4592 - anemia correction", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750190"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy of FG-4592 - Maintenance of hemoglobin levels", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Evaluate the need for anemia rescue therapy, such as blood transfusion, intravenous Iron, or injectable erythrocyte stimulating therapies", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Evaluate changes in vital signs and laboratory values", 
                "measure": "Safety of FG-4592", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Evaluate Adverse Events (AE) and Serious Adverse Events (SAE)", 
                "measure": "FG-4592 Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "FibroGen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Astellas Pharma Europe B.V.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "FibroGen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}